Massachusetts health care law expected to improve access to clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Massachusetts Governor Charlie Baker signed into law a compromise healthcare bill that calls for reimbursing cancer patients for the out-of-pocket expenses associated with clinical trial participation and creating across the board reimbursement programs in the state.

The anticipated result is that thousands of cancer patients in Massachusetts will gain access to advanced treatments offered in clinical trials. The goal is to improve participation and retention in cancer clinical trials, especially among underserved populations.

The legislative action is the result of an effort by Lazarex Cancer Foundation and members of the state legislature, including Representative Hannah Kane, the author and lead on the cancer trial language, Leader Ronald Mariano, former Senator Richard Ross, and others, to bring attention to the issue. Co-authored by Lazarex, the legislation clarifies that reimbursing patients for the out-of-pocket expenses necessary to travel to a clinical trial site are not to be considered inducements or coercion.

Similar legislation is being considered in Florida, and New Mexico, and is already law in California, Pennsylvania, Texas, Illinois and Wisconsin.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login